BiomX Inc. (NYSE:PHGE) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Operator Good morning, and welcome to the BiomX Full Year 2022 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to t ...

Product Development and Trials - The company is developing phage-based therapies targeting harmful bacteria associated with chronic diseases, utilizing a proprietary platform named BOLT [21]. - BX004, targeting Pseudomonas aeruginosa in cystic fibrosis patients, showed a mean reduction of -1.42 log CFU at Day 15 compared to baseline, with no safety events reported [28]. - The Phase 1b/2a trial for BX004 is ongoing, with results from Part 2 expected in Q3 2023, involving 24 CF patients in a 2:1 treatment to placebo ratio [29]. - BX005, targeting Staphylococcus aureus for atopic dermatitis, has shown over 90% efficacy in eradicating antibiotic-resistant strains in preclinical studies [31]. - The FDA approved the IND application for BX005 in April 2022, and the company is evaluating timelines for clinical trials [33]. - The company has paused development of BX003 and CRC programs to prioritize resources for CF and atopic dermatitis initiatives [36][39]. - The company is developing product candidates using phage technology, which has not yet received regulatory approval in the US or EU [192]. - Clinical testing is required to demonstrate safety and efficacy, which can be expensive and time-consuming, particularly for genetically modified phage candidates [196]. - Regulatory approvals for therapeutic indications are expensive and can take many years, with the potential for delays due to additional required studies [204]. - The FDA may require an Advisory Committee to review safety and efficacy data, which could impact approval chances [206]. - Regulatory authorities may approve product candidates for fewer therapeutic indications than requested, affecting commercialization prospects [208]. Financials and Funding - The company received a total of $5 million from the Cystic Fibrosis Foundation to support BX004 development, with $2 million coming after positive trial results [30]. - The company had cash, cash equivalents, and restricted cash of $32.3 million as of December 31, 2022, and anticipates needing to raise additional capital to support operations and product development activities [184]. - In February 2023, the company closed the first part of a PIPE financing, raising approximately $1.5 million in gross proceeds, with a second closing expected to raise an additional $6 million [184]. - The company has a term loan agreement with Hercules for up to $30 million, of which $15 million has been received, but the second tranche of $10 million was not available due to unmet milestones [190]. - The company is obligated to pay a non-refundable license fee of $10,000 per year under the Yeda 2015 License Agreement, along with approximately $2.0 million contributed to the research budget [158]. - Under the Exclusive Patent License Agreement with JSR, the company agreed to pay annual fees ranging from $15,000 to $25,000 and milestone payments up to $3.2 million [164]. - The company faces significant uncertainty regarding the coverage and reimbursement status of products once regulatory approval is obtained [150]. - The company has never generated any revenue from product sales and may never achieve profitability [211]. - The ability to generate meaningful revenue depends on successfully completing development and meeting regulatory requirements [211]. - Significant costs are anticipated for commercializing any approved product, which may require additional funding [212]. Regulatory Environment - The FDA regulates the approval process for new drugs, requiring extensive data on quality, safety, and efficacy before marketing [71]. - The FDA may suspend or terminate clinical trials if patients are exposed to unacceptable health risks [79]. - Phase 1 clinical trials assess metabolism, pharmacologic action, and safety with a small number of participants [81]. - Phase 3 clinical trials involve a large number of patients to demonstrate product effectiveness and safety [81]. - The FDA has 10 months to complete its initial review of a BLA, or 6 months for priority reviews [83]. - Orphan drug designation provides financial incentives and exclusivity for seven years post-approval [87]. - Fast-track designation expedites the review process for drugs addressing serious conditions [88]. - Products may receive accelerated approval if they show effects on surrogate endpoints likely to predict clinical benefit [89]. - Pediatric studies are required to assess safety and efficacy for all relevant pediatric subpopulations [93]. - Manufacturers must comply with cGMP regulations to ensure product quality and safety [96]. - The Biologics Price Competition and Innovation Act allows for an abbreviated approval pathway for biosimilars [98]. - The company is subject to 12 years of data exclusivity for reference biological products from the first licensure date, with a four-year waiting period for biosimilar applications [100]. - Pediatric exclusivity can add six months to existing regulatory exclusivity periods if a pediatric trial is completed as per FDA's request [101]. - Companion diagnostics are utilized to identify patients likely to benefit from therapeutic products, requiring FDA clearance or approval prior to commercialization [102]. - The marketing authorization process in the European Union can take up to 210 days, with a maximum timeframe for evaluation [110]. - Orphan drug designation in the EU provides ten years of market exclusivity post-approval, which can be reduced to six years if criteria are no longer met [115]. - Conditional marketing authorizations in the EU allow for earlier market access based on incomplete clinical data, valid for one year and renewable [118]. - The EMA's PRIME status supports the development and accelerates the approval of innovative medicinal products addressing unmet medical needs [119]. - Pediatric data submission is mandatory for new active substances or new therapeutic indications, with a pediatric investigation plan required [121]. - The company must comply with various foreign regulatory requirements for clinical trials and product approvals, which may differ significantly from U.S. regulations [104]. - The approval process for medicinal products varies by country and may involve additional testing compared to U.S. standards [106]. - The company may apply for a Supplementary Protection Certificate (SPC) to extend patent life beyond current expiration dates, depending on clinical trial lengths and other factors [128]. - A medicinal product with a new active substance is granted eight years of data exclusivity followed by two years of market protection, preventing generics from entering the market during this period [129]. - Biosimilars can be approved through an abbreviated pathway after the expiration of the eight-year data exclusivity period and may be marketed after a 10 or 11-year market protection period [130]. - Market exclusivity for orphan status products prevents the EMA or national authorities from granting another marketing authorization for a similar product for ten years from approval [131]. - Completion of a Pediatric Investigation Plan (PIP) can lead to a pediatric reward, which may include a six-month extension of SPC or two additional years of market exclusivity for orphan products [132]. Competition and Market Dynamics - The biotechnology and pharmaceutical industries are characterized by strong competition, with key factors including efficacy, safety, and intellectual property protection [66]. - The company faces competition from larger pharmaceutical companies and other biotechnology firms with greater resources and experience [67]. - The commercial success of drug candidates will depend on market acceptance and physician adoption [214]. - High titers for specific phage cocktails necessary for testing may be difficult and time-consuming to achieve [216]. - Preclinical study results may not predict outcomes in clinical trials, leading to potential setbacks [217]. - Regulatory approval processes are extensive and could delay or prevent marketing of product candidates [220]. Operational Challenges - The company plans to continue prioritizing its ongoing CF program while implementing a 50% reduction in personnel as part of its corporate restructuring plan announced in May 2022 [172]. - As of December 31, 2022, the company employed 54 full-time and 11 part-time employees, with 50 engaged in research and development and clinical activities [171]. - The company has not laid off any employees due to the COVID-19 pandemic and has implemented safety measures to ensure employee well-being [173]. - The company is focused on expanding its clinical product pipeline and anticipates significant expenses related to research and development and clinical trials in the foreseeable future [182]. - The company may seek funds through collaborations that could require relinquishing rights to product candidates, potentially affecting future development [184]. - The company faces risks related to market volatility and economic conditions that could adversely affect its ability to raise funds and impact its stock price [186]. - The Hercules Loan Agreement includes affirmative covenants requiring the company to maintain legal existence and deliver financial reports, and negative covenants restricting additional indebtedness and mergers [191]. - The ongoing COVID-19 pandemic has caused significant disruptions, including delays in patient enrollment and clinical trial operations [197]. - The complexity of genetically modified phage therapy may extend the time required for regulatory approval [220]. Legal and Compliance Issues - The company is subject to various federal and state laws targeting fraud and abuse in the healthcare industry, which may impact business operations [134]. - Violations of fraud and abuse laws may result in significant penalties, including fines, imprisonment, and exclusion from federal healthcare programs [138]. - The company must comply with environmental protection laws, which govern the handling and disposal of hazardous substances used in operations [143]. - The U.S. Foreign Corrupt Practices Act prohibits bribery of foreign officials to obtain or retain business, with similar laws in other countries [144]. - The Affordable Care Act (ACA) has led to increased Medicaid rebates and new methodologies for calculating rebates for certain drugs, impacting reimbursement rates [145]. - The Budget Control Act of 2011 and the Bipartisan Budget Act of 2015 resulted in a 2% reduction in Medicare payments to providers, effective through 2030 [148]. - The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap starting January 1, 2024, potentially affecting drug pricing [146]. - The Inflation Reduction Act allows Medicare to negotiate drug prices for high-expenditure, single-source drugs, impacting pharmaceutical pricing strategies [148].

Financial Data and Key Metrics Changes - As of September 30, 2022, cash balance and short-term deposits were $41.5 million, down from $63.1 million as of December 31, 2021, primarily due to net cash used in operating activities [13] - Net loss for Q3 2022 was $6.8 million, compared to $10 million for the same period in 2021 [16] - Net cash used in operating activities for the nine months ended September 30, 2022, was $21.9 million, compared to $18.5 million for the same period in 2021 [16] Business Line Data and Key Metrics Changes - Research and development expenses were $3.5 million for Q3 2022, down from $6.6 million for the same period in 2021, reflecting a decrease in salaries and related expenses due to corporate restructuring and paused development of certain product candidates [14] - General and administrative expenses were $2.6 million for Q3 2022, compared to $2.8 million for the same period in 2021, also reflecting a decrease in salaries and related expenses due to corporate restructuring [15] Market Data and Key Metrics Changes - The company is focused on the ongoing Phase Ib/IIa trial of BX004 in cystic fibrosis, with an expected completion of enrollment in Part 1 by year-end 2022 and results anticipated in Q1 2023 [9][10] Company Strategy and Development Direction - The company aims to advance the BX004 program as a treatment for cystic fibrosis patients with chronic respiratory infections caused by Pseudomonas aeruginosa, emphasizing the importance of ongoing research and development efforts [10][18] - The company is also pursuing preclinical activities for BX005 in atopic dermatitis, working with Maruho on formulation and planning for future clinical trials [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in patient enrollment due to COVID-19 and the holiday season but noted an uptick in enrollment trends due to improved mechanisms and increased site numbers [22][23] - The company remains optimistic about the future of phage therapy and its potential impact on cystic fibrosis treatment [27][34] Other Important Information - The company estimates that existing cash, cash equivalents, and short-term deposits are sufficient to fund its current operating plan at least through mid-2024 [16] Q&A Session Summary Question: Can you define the enrollment-enhancing mechanisms discussed? - Management noted initial enrollment was slower than anticipated due to COVID-19 and holidays, but they have implemented mechanisms to improve interaction with CROs and increased the number of sites [22][23] Question: What is the real-world impact from the holidays on scheduling and analyses? - Management indicated that the holidays had some impact, but they are optimistic about the recent uptick in enrollment [22] Question: Were there any amendments made to the trial? - Management confirmed no significant amendments were made, focusing instead on adding additional sites [26] Question: Is the atopic dermatitis program still a priority? - Management stated that while the focus is currently on cystic fibrosis, they are working with Maruho on the atopic dermatitis program and will reassess once progress is made [30]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other juris ...

BiomX Inc. (NYSE:PHGE) Q2 2022 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Marina Wolfson - Chief Financial Officer Jonathan Solomon - Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kristen Kluska – Cantor Fitzgerald Michael Higgins - Ladenburg Thalmann Keay Nakae - Chardan Operator Good morning. And welcome to BiomX Second Quarter 2022 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission file number: 001-38762 BiomX Inc. FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in Its Charter) | Delaware | 82-3364020 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | inco ...

BiomX Inc. (NYSE:PHGE) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Operator Good morning. And welcome to BiomX First Quarter 2022 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. There will be question-and-answer session at the end of this call. I'll now like to turn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 0001-38762 BIOMX INC. (Exact name of registrant as specified in its charter) | Delaware | 82-3364020 | | --- | --- | | (State or othe ...

BiomX Inc. (NYSE:PHGE) Q4 2021 Earnings Conference Call March 30, 2022 8:00 AM ET Company Participants Jonathan Solomon – Chief Executive Officer Marina Wolfson – Senior Vice President of Finance Conference Call Participants Joe Pantginis – H.C. Wainwright Keay Nakae – Chardan Capital Operator Greetings, welcome to BiomX Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode, and question-and-answer session will follow ...